General Information of Drug (ID:
DR5749) |
Drug Name |
Ivosidenib
|
Synonyms |
(2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide; Ivosidenib; Ivosidenib (USAN/INN); Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; Tibsovo
|
Indication |
Acute myeloid leukaemia
[ICD11: 2A60]
|
Approved
|
[1]
|
Hepatocellular carcinoma
[ICD11:
ICD11: 2C12]
|
Phase 3
|
[2]
|
Acute lymphoblastic leukemia
[ICD11:
ICD11: 2B33]
|
Phase 1
|
[3]
|
Structure |
|
|
3D MOL
|
2D MOL
|
Pharmaceutical Properties |
Molecular Weight |
582.968 |
Topological Polar Surface Area |
119 |
Heavy Atom Count |
41 |
Rotatable Bond Count |
7 |
Hydrogen Bond Donor Count |
1 |
Hydrogen Bond Acceptor Count |
9 |
Cross-matching ID |
- PubChem CID
- 71657455
- CAS Number
-
- Formula
- C28H22ClF3N6O3
- Canonical SMILES
- C1CC(=O)N(C1C(=O)N(C2=CC(=CN=C2)F)C(C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N
- InChI
- InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1
- InChIKey
- WIJZXSAJMHAVGX-DHLKQENFSA-N
|
|
|
|
|
|
|
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.